{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:19:54Z","timestamp":1783052394656,"version":"3.54.6"},"reference-count":4,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.bulcan.2023.12.014","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T07:53:52Z","timestamp":1709798032000},"page":"336-337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Talquetamab\u00a0\u2013\u00a0my\u00e9lome multiple en quatri\u00e8me ligne"],"prefix":"10.1016","volume":"111","author":[{"given":"Thomas","family":"Fatrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Chalayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bulcan.2023.12.014_bib0025","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2023.12.014_bib0030","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2022-159707","article-title":"Talquetamab, a G protein-coupled receptor family C group 5\u00a0member D x CD3\u00a0bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): phase 1\/2\u00a0results from MonumenTAL-1","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.12.014_bib0035","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jdcr.2022.11.013","article-title":"Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma","volume":"31","author":"Narayan","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"16_suppl.","key":"10.1016\/j.bulcan.2023.12.014_bib0040","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal)+daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2\u00a0results","volume":"41","author":"Dholaria","year":"2023","journal-title":"JCO"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:38:24Z","timestamp":1757792304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":4,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0007455124000493"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.12.014","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Talquetamab\u00a0\u2013\u00a0my\u00e9lome multiple en quatri\u00e8me ligne","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}